Related Experiment Videos
[Prenatal, neonatal and postnatal prevention in cystic fibrosis]
J Frézal1, M L Briard, J P Farriaux
1Prévention des Handicaps de l'Enfant, Hôpital des Enfants Malades, Paris.
Insights
Improving neonatal screening for cystic fibrosis (CF) involves adding molecular analysis to the immunoreactive trypsin test. While carrier screening is beneficial for relatives, general population screening for CF carriers is not yet recommended.
Area of Science:
- Medical Genetics
- Neonatal Screening
- Cystic Fibrosis Research
Background:
- Neonatal screening for cystic fibrosis (CF) currently relies on the immunoreactive trypsin test.
- The addition of molecular analysis to existing screening methods could enhance efficiency.
- The overall benefit of expanded CF screening programs remains under discussion.
Purpose of the Study:
- To evaluate the potential improvements in neonatal screening for CF by integrating molecular analysis.
- To discuss the role and limitations of antenatal diagnosis in managing CF incidence.
- To assess the feasibility and implications of carrier screening programs for CF.
Main Methods:
- Analysis of dried blood samples for both immunoreactive trypsin levels and CFTR gene mutations.
- Review of current antenatal diagnostic procedures for CF.
- Evaluation of the ethical and practical considerations for carrier detection programs.
Main Results:
- Combining molecular analysis with the immunoreactive trypsin test on a single dried blood sample can improve neonatal screening efficiency for CF.
- Antenatal diagnosis, while important, has a limited impact on overall CF incidence if implemented post-birth.
- Carrier detection is valuable for patient relatives but not yet advisable for the general population.
Conclusions:
- Integrated molecular and biochemical testing offers a more efficient approach to neonatal CF screening.
- Antenatal diagnosis alone cannot significantly reduce CF incidence without broader screening strategies.
- Carrier screening for CF is beneficial within specific familial contexts but requires further consideration for widespread implementation.
Abstract:
The efficiency of neonatal screening for CF could be improved by associating a molecular analysis to the immunoreactive trypsin test, on the same dried blood's sample. However the interest of such a screening for the patients benefit remains controversial. In most cases, antenatal diagnosis may be performed by a direct search of the mutation(s). However, the impact of antenatal diagnosis on CF's incidence will necessarily be limited if it can only be implemented after the birth of an affected child. Hence the interest of screening programs for the detection of healthy carriers. Carrier's detection does not raise any objection for the relatives of patients. It is still premature to recommend it to be undertaken in the general population.